Gastric inhibitory polypeptide

1. Gastric inhibitory polypeptide increases myotube thickness in human cells.

   “Neither treatment impaired myotube thickness or differentiation; GIP increased myotube thickness after 8 days.”

   Cellsin primary human myotubesskeletal muscle8 days

   GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes

   bioRxiv (Cold Spring Harbor Laboratory)·23 Jul 2026Preprint

More on Myotube thickness

1. Gastric inhibitory polypeptide has no effect on atrophy-related gene expression in human cells.

   “Neither semaglutide nor GIP altered atrophy-related gene expression or the secretome, with no proteins reaching significance.”

   Cellsin primary human myotubesskeletal muscle

   GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes

   bioRxiv (Cold Spring Harbor Laboratory)·23 Jul 2026Preprint

More on Atrophy-related gene expression

1. Gastric inhibitory polypeptide prevents apoptosis in human cells.

   “GIP prevented apoptosis, but not autophagy”

   Cellscardiac progenitor cells

   Tirzepatide Prevents Palmitate-Induced Apoptosis, Autophagy, and Senescence in Human Cardiac Progenitor Cells

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Apoptosis

1. Gastric inhibitory polypeptide inhibits SIRT1 in mouse cells.

   “GIP suppressed α-lipoic acid-induced Sirt1 expression and activity in differentiated adipocytes.”

   Cellsin differentiated adipocytes treated with alpha-lipoic acid

   Inhibition of GIP signaling extends lifespan without caloric restriction

   Biochemical and biophysical research communications·17 Apr 2019

More on SIRT1